Compare Ginkgo Bioworks Holdings Inc (DNA) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Intuitive Surgical, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 192.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Intuitive Surgical, Inc. for 84 Days on average.
| DNA | ISRG | |
|---|---|---|
Market Cap | $763.64M | $146.76B |
Volume | 3,204,177 | 2,529,814 |
Sector | Health | Health |
52-Week High | $15.83 | $592.85 |
52-Week Low | $5.48 | $332.02 |
Typical Hold Time | 7 Days | 84 Days |
Enterprise Value | $865.59M | $141.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with a negative net income margin of -219.6%. Recent news includes a partnership with TuneLab and a $17.5 million ARPA-H subcontract.
The outlook is challenged by persistent losses and negative cash flow, though strategic partnerships offer growth potential. Analyst sentiment is divided evenly between buy, hold, and sell ratings. Key risks include execution on profitability and high cash burn. The stock presents a speculative opportunity dependent on the company's ability to monetize its technology platform.
Intuitive Surgical (ISRG) trades at $415.41, up 0.21% with a bullish technical outlook. The stock shows strong fundamentals with 2025 revenue of $10.06B and net income of $2.86B, maintaining consistent earnings beats. Valuation metrics remain elevated with a P/E of 47.64 and P/S of 13.54, reflecting premium pricing for the robotic surgery leader. Recent news highlights international expansion in India and Japan to offset China weakness, while da Vinci 5 upgrades and ASC market penetration drive growth.
ISRG presents a compelling growth story with dominant market position and expanding global footprint, though premium valuation requires sustained execution. Key risks include procedure growth moderation and competitive pressures. Analyst consensus remains strongly bullish with $480.78 price target representing 16% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
